Onco Actu du 20 juin 2017

	1. Biologie
Researchers Develop Human Tissue Platform to Test Drugs for Colon Cancer [Oncology Times] The first-ever "disease in a Petri dish" platform that models human colon cancer derived from stem cells has been developed by Weill Cornell Medicine investigators, allowing them to identify a targeted drug treatment for a common, inherited form of the disease. The discovery also overcomes a longstanding challenge of using mice to research this form of cancer, as they do not typically develop the disease.
	2.5 Etiologie - Gènes
More thoughts, and just plain provocateuring, on genomic causal complexity. . . . [The Mermaid's Tale] Moving the Big Money that has been locked up by the current haves, to redistribute to more important-payoff kinds of research would inevitably meet resistance, including from NIH's head office, which has been a sloganeering center that makes PT Barnum look like an amateur.
Omnigenic drug discovery [PLENGE GEN] For most disease-associated variants, the effect on biological function is not yet known. This is a major gap that needs to be filled if genetics is to be used in drug discovery and development.
	3.1.1 Tabac - e-cigs
Occasional smokers who vape smoke more cigarettes [Reuters] “The participants who were vaping ended up using more cigarettes. It’s actually a risk factor for increasing their cigarette use.”
	4. Dépistage, diagnostic et pronostic
Giles Maskell: The practice of radiology needs to change [BMJ Blogs] I am as wary as the next doctor of drawing parallels between medicine and aviation, but most passenger flights do not rely on a single pilot in the cockpit. Should we? By persisting with outdated working practices we are putting patients at greater risk of an incorrect or delayed diagnosis, and radiologists at risk of the consequences of making a significant error.
	4.12 Biopsies liquides
Blood test may show if prostate cancer treatment is working [NHS Choices] Though the findings show promise, this study only looked at blood samples taken from a relatively small sample of 46 men. Only six of these men had gene mutations linked to a poor prognosis.
	4.2 Dép., diag. & prono. - Génome
Catalyzing Integration of Genomic and Clinical Datasets Across Multiple Cancer Institutions Worldwide [ESMO] The AACR Project GENIE enables precision cancer medicine research.
	5. Traitements
Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer, Roswell Park Researchers Show [Roswell Park Cancer Institute] First clinical study to show benefit of surgery following SBRT, and to demonstrate that SBRT stimulates immune system.
Immune Cells Deliver Cancer Drugs to the Brain [The Scientist] Neutrophils loaded with the chemotherapy drug paclitaxel traverse the blood-brain barrier and kill residual cancer cells after tumor-resection surgery.
Bedside drug production will truly enable personalized medicine [STAT] Personalized medicines will most likely initially focus on biopharmaceuticals such as proteins, peptides, and monoclonal antibodies. These can be adapted to an individual patient’s needs with relative ease.
	5.10 Traitements - Essais
Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit with Single Agent Imbruvica®▼ (ibrutinib) vs Temsirolimus at First Relapse in Mantle Cell Lymphoma [Janssen] "These data add to the growing body of evidence which shows that using ibrutinib earlier in the treatment pathway may have significant benefits for patients.”
	5.12 Immunothérapies
Discovery could guide immunotherapy for lung cancer [Cancer Research UK] “These are hugely exciting results. For the first time we have a real indication of who might benefit from a particular drug before we make treatment decisions.
Scientists find new biomarker to guide cancer immunotherapy [Reuters] The latest research adds a further twist by highlighting the role of so-called tissue-resident memory T-cells.
	5.12.1 Immunothérapies - partenariats
Parker-Tessa alliance tees up solid tumor I-O combinations [FierceBiotech] Partnering with the Parker Institute connects Tessa to Memorial Sloan Kettering Cancer Center, Stanford University, UCLA, UCSF, the University of Pennsylvania, and MD Anderson Cancer Center.
	5.2 Pharma
Seattle Genetics stops all trials of '33A blood cancer drug after patient deaths [FierceBiotech] It's a big blow to the company as well as AML patients and their carers, particularly as data reported at the American Society of Hematology meeting last December showed a complete remission rate of 70% with the drug.
SeaGen Ends One Leukemia Drug Trial, Stops Enrolling Three Others [Xconomy] The SeaGen drug is one of the company’s antibody drug conjugates (ADC), a type of cancer therapy that links powerful anti-cancer compounds to targeting antibodies to deliver a precise strike to cancer cells.
Slammed by more deaths, Seattle Genetics scraps a PhIII study and pulls back (again) on vadastuximab [EndPoints] The latest safety crisis will hit Seattle Genetics hard.
Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine (SGN-CD33A) in Frontline Acute Myeloid Leukemia [Seattle Genetics] Seattle Genetics is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials including the ongoing phase 1/2 clinical trial in frontline high risk myelodysplastic syndrome (MDS).
Seattle Genetics halts late-stage study of leukemia drug [Reuters] The drug, vadastuximab talirine, was being evaluated in the late-stage study, Cascade, to treat a form of blood cancer called acute myeloid leukemia (AML). Seattle Genetics declined to disclose the number of deaths, but said they were not related to liver toxicity, based on available data.
	5.2.3 Pharma - économie
Current biopharma R&D costs ‘unsustainable’, warns report [PharmaTimes] The detrimental effect of this downturn, coupled with “aggressive pricing pressures” around the globe, has been magnified by a persistently high development cost for new medicines, which is estimated to range from $1 billion to $2.5 billion per product.
	5.4 Traitements - Economie
The Future of Oncology Treatment and Value Assessment [Healthcare Economist] Value frameworks are all the rage of late. But are payers really using them? According to my colleague Jeremy Schafer, the answer is yes.
	5.5 ASCO
ASCO 2017: 4 ways treatment could change following world’s largest cancer conference [Cancer Research UK] Each of these areas is focused on finding treatments that are most likely to work for each patient. And after 5 days of talks, with thousands of pieces of research on show, the challenge now is keeping up.
	5.5.3 ASCO (prostate)
Abiraterone Improves Survival for Some Men with Hormone-Sensitive Prostate Cancer [NCI] “While the [abiraterone] data are exciting, there is no clear evidence that [either] abiraterone or docetaxel is superior for patients with metastatic, castration-sensitive disease,” said Dr. Madan. “Therefore, both are options for this population. It may be preferred to tailor treatment to patients based on patient preferences and comorbidities.”
	6. Lutte contre les cancers
Long-term Survivorship Care after Cancer Treatment: A Workshop [National Academies] The National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine will hold a public workshop in July 2017 to examine progress in cancer survivorship care over the past decade and to consider potential actions to improve the planning, management, and delivery of cancer survivorship care.
Results are in for Europe’s First Biobanking Study on HPV Cervical Cancer [Labiotech.eu] The RAIDs consortium made its closing event last week. After 4.5 years of studies, it has managed to change our appreciation of HPV cervical cancer towards building intelligent targeted therapy designs.
‘Human Project’ study will ask 10,000 to share life’s data [STAT] They’ll start with tests of everything from blood to genetics to IQ. They’ll be asked for access to medical, financial, and educational records, as well as cellphone data such as location and the numbers they call and text. They’ll also be given wearable activity trackers, special scales, and surveys via smartphone. Follow-up blood and urine tests — and an at-home fecal sample — will be requested every three years.
	6.10 Politiques
Macron consolidates electoral victory [Nature] The party of France’s recently elected president won an absolute majority in its first general elections, with an agenda that included strong support for research.
	6.10.1 Politiques (USA)
If drug companies are really ‘getting away with murder,’ Trump may be about to grant them a pardon [STAT] Right now, it’s hard to see how this effort will do anything but drain American wallets.
	6.6 Publications
Microsoft Academic is on the verge of becoming a bibliometric superpower [LSE Impact Blog] Microsoft Academic combines the following features of existing databases: a broad coverage (Google Scholar), structured and rich metadata as well as functionality (Scopus and Web of Science), and a social network for academics (ResearchGate). In addition, accessing raw data is relatively cheap.
	6.7 DMP, Big Data & applis
Apple is working with this small start-up to change how we track our health [CNBC] Health Gorilla specializes in aggregating diagnostic information, such as blood work, into one place.